Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
A JAMA review revealed that only 26% of pediatric ABRS patients treated with placebo required subsequent antibiotic therapy, prompting questions about current guidelines recommending first-line antibiotic use in children with sinusitis.
Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.